ADXS:OTC-Advaxis Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 4.06

Change

0.00 (0.00)%

Market Cap

USD 3.69M

Volume

8.20K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ADXS Stock Forecast & Price:
Based on the Advaxis Inc stock forecasts from 0 analysts, the average analyst target price for Advaxis Inc is not available over the next 12 months. Advaxis Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Advaxis Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Advaxis Inc’s stock price was USD 4.06. Advaxis Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -85.68% over the last year.

No recent analyst target price found for Advaxis Inc
No recent average analyst rating found for Advaxis Inc

About Advaxis Inc (ADXS:OTC)

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinic ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.38 (-0.31%)

USD288.42B 38.66 3.54
CMXHF CSL Limited

+1.98 (+1.00%)

USD98.64B 42.61 28.39
CSLLY CSL Ltd

+0.81 (+0.81%)

USD96.65B 41.75 28.39
GNMSF Genmab A/S

+2.40 (+0.53%)

USD30.42B 36.92 3.71
WXXWY WuXi Biologics (Cayman) Inc

-0.36 (-2.63%)

USD28.61B 46.76 5.57
WXIBF WuXi Biologics

N/A

USD28.19B 51.38 5.57
ARGNF argenx SE

N/A

USD22.32B N/A -22.20
UCBJF UCB SA

N/A

USD15.22B 16.65 10.95
UCBJY UCB SA ADR

+1.03 (+2.76%)

USD14.26B 15.57 10.95
SHJBF Shanghai Junshi Biosciences Co..

N/A

USD13.48B N/A -4.32

ETFs Containing ADXS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -67.38% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.38% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -85.90% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.90% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.89% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.89% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -55.33% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.33% 1% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.74% 75% C 52% F
Risk Adjusted Return -120.98% 3% F 1% F
Market Capitalization 3.69M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.13 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.24 N/A N/A N/A N/A
EV/EBITDA 1.62 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -41.98% N/A N/A N/A N/A
Return on Invested Capital -54.54% N/A N/A N/A N/A
Return on Assets -24.13% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.95 N/A N/A N/A N/A
Short Percent 2.19% N/A N/A N/A N/A
Beta 2.28 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.